Glutaminase therefore serves as a logical target for inhibition of tumor metabolism, and preclinical studies of the glutaminase inhibitor CB-839 demonstrated efficacy in slowing tumor cell growth (26–28). The gene discussed is GLS; the disease is neoplasm.